Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bruce D. Steel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 2.04
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 15.09
Financials
Revenue
$0.00-100.0%Net Income
$-4.69MEBITDA
$-5.08MFree Cash Flow
$-4.18MEPS (diluted)
$-0.04Shares Outstanding (diluted)
111.81M+857.3%Operating Expenses
$5.16MCash & Debt
$57.16MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-22.40M | $-0.39 |
| 2024 | $41.09M | $-8.07M | $-0.23 |
| 2023 | $36.08M | $-13.34M | $-0.38 |
| 2022 | $15.76M | $-62.43M | $-3.19 |
| 2021 | $0.00 | $-38.98M | $-1.35 |
| 2020 | $0.00 | $-29.81M | $-1.46 |
| 2019 | $0.00 | $-25.58M | $-1.47 |
| 2018 | $0.00 | $-13.25M | $-1.09 |
| 2017 | $0.00 | $-2.26M | $-0.13 |
Valuation
EQhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-42.86%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·27d ago·Negative
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in additional funding under previously announced equity private placement agreement; cash expected to fund currently planned operations into 2029 LA JOLLA, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. …
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Equillium Announces Poster Presentations at the 7th International AHR Conference New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation
View source ↗ - Newsmarketbeat.com·56d ago·Negative
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat.
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.
View source ↗ - Newsreuters.com·68d ago·Positive
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
View source ↗
Earnings
Typical surprise +25.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.04 vs $-0.05beat
- Wed, May 13$-0.06 vs $-0.04miss
- Wed, Mar 25$-0.04 vs $-0.07beat
- Thu, Nov 13$-0.06 vs $-0.14beat
- Thu, Aug 14$-0.16 vs $-0.14miss
- Wed, May 14$-0.24 vs $-0.23miss
Estimates and results for EQ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EQ officers and directors.
- Bought
- —
- Sold
- $2.8m
0 trades
20 trades
- Zedelmayer Christinesold
- Connelly Stephensold
- Connelly Stephensold
- Tom Pennysold
- Zedelmayer Christinesold
- Zedelmayer Christinesold
- Zedelmayer Christinesold
- Zedelmayer Christinesold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EQ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
